Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
2024 ASCO Annual Meeting
Novartis is at the 2024 ASCO Annual Meeting from May 31 to June 4, 2024.
Latest news
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
The burden of IgAN
IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Welcome to where we thrive together
Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives.